Add like
Add dislike
Add to saved papers

Sunlight driven photolytic ozonation as an advanced oxidation process in the oxidation of bezafibrate, cotinine and iopamidol.

Water Research 2018 December 22
This study investigates the efficacy of the system O3 /sunlight radiation compared to dark ozonation when treating pharmaceuticals compounds of different reactivity, namely bezafibrate, cotinine, and iopamidol. Results show the beneficial effects of simulated sunlight radiation (300-800 nm) when treating ozone recalcitrant compounds such as cotinine and iopamidol. The system O3 /sunlight radiation increased mineralization extent in all cases if compared to dark ozonation. Transformation products identified in individual runs suggest that amine oxidation and further alkyl chain attack is the main route of bezafibrate ozonation. Hydroxylation seems to be the preferential path in cotinine abatement while H abstraction from alcoholic moieties is suggested in the case of iopamidol. Toxicity of intermediates was approximately evaluated by QSAR methodologies and experimentally through Daphnia Magna survival after 24 h. As a rule of thumb, initial intermediates generated are even more toxic than parent compounds, however, after 120 min of treatment, toxicity significantly decreased. Amongst the most toxic compounds generated: 4-Chlorobenzoyltyramine, and 4-Chloro-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-benzamide (from bezafibrate), and N-(2-Hydroxy-1-hydroxymethyl-ethyl)-N'-(1-hydroxymethyl-2-oxo-ethyl)-5-(2-hydroxy-propionylamino)-2,4,6-triiodo-isophthalamide, N,N'-Bis-(1-hydroxymethyl-2-oxo-ethyl)-5-(2-hydroxy-propionylamino)-2,4,6-triiodo-isophthalamide, and N-(1-Hydroxymethyl-2-oxo-ethyl)-5-(2-hydroxy-propionylamino)-2,4,6-triiodo-isophthalamide (from iopamidol) were identified.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app